StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Gain Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Gain Therapeutics's total assets was $15.42M at Jun 30, 2026. For fiscal 2025 it was $22.82M, up 88.2% from the year before. The highest annual figure on record is $38.99M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$22.82M+88.2%
FY2024Dec 31, 2024$12.12M-34.9%
FY2023Dec 31, 2023$18.61M-22.8%
FY2022Dec 31, 2022$24.10M-38.2%
FY2021Dec 31, 2021$38.99M+305.9%
FY2020Dec 31, 2020$9.60M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$15.42M+56.8%
Q1 FY2026Mar 31, 2026$18.74M+61.2%
Q4 FY2025Dec 31, 2025$22.82M+88.2%
Q3 FY2025Sep 30, 2025$10.97M-23.6%
Q2 FY2025Jun 30, 2025$9.83M-48.8%
Q1 FY2025Mar 31, 2025$11.62M-20.3%
Q4 FY2024Dec 31, 2024$12.12M-34.9%
Q3 FY2024Sep 30, 2024$14.37M+1.9%
Q2 FY2024Jun 30, 2024$19.20M+5.1%
Q1 FY2024Mar 31, 2024$14.58M-31.6%
Q4 FY2023Dec 31, 2023$18.61M-22.8%
Q3 FY2023Sep 30, 2023$14.10M-50.2%
Q2 FY2023Jun 30, 2023$18.26M-42.7%
Q1 FY2023Mar 31, 2023$21.32M-43.3%
Q4 FY2022Dec 31, 2022$24.10M-38.2%
Q3 FY2022Sep 30, 2022$28.33M-33.4%
Q2 FY2022Jun 30, 2022$31.89M-29.7%
Q1 FY2022Mar 31, 2022$37.60M-21.7%
Q4 FY2021Dec 31, 2021$38.99M+305.9%
Q3 FY2021Sep 30, 2021$42.56M–
Q2 FY2021Jun 30, 2021$45.35M–
Q1 FY2021Mar 31, 2021$48.04M–
Q4 FY2020Dec 31, 2020$9.60M–

More Gain Therapeutics figures

See a number that looks wrong?